EDAP TMS SA (FOCL): Results of Operations and Financial Condition
EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal thera
How this was made
The 30-second read
Why it matters
Q2 continuing-operations performance shows 39% YoY revenue growth to $13.2M and gross margin expansion to 55.6%, while net loss widened to $14.4M largely due to a $5.5M European Investment Bank warrant valuation impact. The company also announced an underwritten public offering for $40M gross proceeds expected to close Aug. 14, 2026, creating a near-term dilution and liquidity catalyst.
Market read
This is a combined fundamentals and event-risk update: continuing-operations growth and margin improvement alongside a scheduled financing close next week.
What to watch
Discontinued operations reclassification (ESWL and Distribution held for sale) changes comparability; traders should focus on continuing-operations metrics and watch for any offering terms not included in this excerpt.
Background
SEC 8-K Item 2.02 with Exhibit 99.1 reporting Q2 2026 financial results and reiterating 2026 guidance, after reclassifying ESWL and Distribution as discontinued operations.
Ticker impact
FocalTherics reported Q2 2026 HIFU results and reiterated 2026 revenue guidance, plus disclosed a $40M underwritten public offering expected to close Aug. 14.
Near-term volatility likely around the offering close and any follow-through on guidance credibility; direction depends on whether investors view the financing as supportive runway versus dilution.
The article provides concrete Q2 operating metrics and guidance ranges, and it explicitly states the offering size and expected closing date, both of which are actionable for positioning and event-risk management.
Market effects
Robotic focal therapy and focused ultrasound device peers may see read-across on commercial adoption metrics (installed base, procedure growth) and financing appetite.
U.S. procedure volume growth (47% YoY) highlights demand momentum that can influence investor sentiment toward U.S.-commercialized medtech platforms.
Europe endometriosis program launch and EIB warrant valuation impact underscore cross-region execution and financing structure sensitivity.
Counterpoint
The headline HIFU growth and gross margin improvement may be partially offset by elevated operating expenses and warrant valuation effects, so the financing could be interpreted as funding needs rather than purely growth capital.
Key entities
- issuerFocalTherics
Robotic focal therapy company reporting Q2 2026 HIFU continuing-operations results and 2026 guidance, and announcing a $40M underwritten public offering.
- executiveRyan Rhodes
CEO quoted on commercial momentum, endometriosis program launch, and growth plans across indications.
- financing counterpartyEuropean Investment Bank
Warrant valuation impact of $5.5M cited as a driver of increased net loss in Q2.
